Results 41 to 50 of about 423,879 (287)

Gouty arthritis of the spine in a renal transplant patient : a clinical case report: an unusual presentation of a common disease [PDF]

, 2015
Axial gout is a well-documented but uncommon manifestation of gout. Its mimicking nature and the impracticality of axial joint aspiration might considerably delay its diagnosis.
Dhaese, Sofie, STRYCKERS, MARIJKE, Terryn, Wim, VAN DER MEERSCH, HANS, Van Laecke, Steven   +4 more
core   +1 more source

Cardiac and renal protective effects of urate-lowering therapy [PDF]

Rheumatology, 2017
Patients with gout often have co-morbidities such as cardiovascular disease, renal failure and metabolic syndrome components. Some studies, but not all, have suggested that hyperuricaemia and gout are associated with increased risk of myocardial infarction, renal failure and death primarily because of increased risk of cardiovascular events. Therefore,
Pascal, Richette, Augustin, Latourte, Thomas, Bardin   +2 more
openaire   +2 more sources

Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares. [PDF]

Rheumatology (Oxford), 2023
Objectives To evaluate a strategy designed to optimize care and increase uptake of urate-lowering therapy (ULT) during hospitalizations for gout flares.
Russell MD, Ameyaw-Kyeremeh L, Dell'Accio F, Lapham H, Head N, Stovin C, Patel V, Clarke BD, Nagra D, Alveyn E, Adas MA, Bechman K, de la Puente MA, Ellis B, Byrne C, Patel R, Rutherford AI, Cantle F, Norton S, Roddy E, Hudson J, Cope AP, Galloway JB.   +22 more
europepmc   +2 more sources

Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). [PDF]

, 2017
In November 2016, the American College of Physicians (ACP) published a clinical practice guideline on the management of acute and recurrent gout. This guideline differs substantially from the latest guidelines generated by the American College of ...
A Chhana, A Qaseem, A Qaseem, AB Gutman, Alexander K. So, CF Kuo, CY Lam Erwin, D Khanna, D Khanna, DF Ransohoff, DH Solomon, DJ McCarty, DJ McCarty, DL Sackett, E Jutkowitz, E Pascual, F Lioté, F Perez-Ruiz, F Perez-Ruiz, F Perez-Ruiz, F Rees, F Sivera, Frédéric Lioté, H Park, HK Choi, HR Schumacher, HR Schumacher, HR Schumacher Jr., HS Baraf, Hyon K. Choi, J Li-Yu, JA Singh, JA Singh, JE Seegmiller, JN Loeb, JS Faires, JS Sundy, Kenneth G. Saag, KG Saag, Lisa K. Stamp, LK Stamp, M Doherty, MA Becker, MA Becker, MA Becker, MA Becker, Michael Doherty, N Bellamy, N Dalbeth, N Dalbeth, N Dalbeth, N Dalbeth, Nicola Dalbeth, O Aati, P Richette, P Richette, Pascal Richette, PC Robinson, PG Shekelle, PP Khanna, PS Hench, R Halpern, R Jackson, RM McLean, Robert Terkeltaub, SI Hung, SY Lim, T Bardin, T Neogi, Thomas Bardin, TM Ko, U Kiltz, V Strand   +72 more
core   +1 more source

Contentious Issues in Gout Management: The Story so Far

Open Access Rheumatology: Research and Reviews, 2021
Mohamed Talaat,1 Kyle Park,1 Naomi Schlesinger2 1Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903-0019 ...
Talaat M, Park K, Schlesinger N
doaj  

Gout [PDF]

, 2008
INTRODUCTION: Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years. METHODS AND OUTCOMES:We conducted a systematic review and aimed to answer the following clinical questions: What are the
Underwood, Martin
core   +3 more sources

Bariatric surgery as urate-lowering therapy in severe obesity [PDF]

Annals of the Rheumatic Diseases, 2014
Gout represents a metabolically driven inflammatory arthropathy, which could be substantially influenced by adiposity and lifestyle risk factors. As such, influenced by the trends in lifestyle factors associated with Westernisation,1 ,2 gout prevalence has increased in the last few decades worldwide (eg, 3.9% of US adults (8.3 million) in 2007–20083).4
Hyon K, Choi, Yuqing, Zhang
openaire   +2 more sources

Urate-Lowering Therapy Use among US Adults with Gout and the Relationship between Patients’ Gout Treatment Status and Associated Comorbidities

Rheumato, 2023
Gout is one of the most common inflammatory conditions with a growing global prevalence. Individuals with gout are at higher risk of developing chronic conditions, such as diabetes, chronic kidney disease (CKD), and cardiovascular diseases. In this study,
Marcos Ortiz-Uriarte, Jeanlouis Betancourt-Gaztambide, Alexandra Perez, Y. Roman   +3 more
semanticscholar   +1 more source

Experience with canakinumab in a patient with gout and IgA nephropathy

Современная ревматология, 2019
The paper discusses the results of clinically using the interleukin-1_ inhibitor canakinumab in a patient with chronic tophaceous gout, IgA nephropathy, and chronic kidney disease with resistance to traditional anti-inflammatory drugs (colchicine ...
E. V. Ilyinykh, M. S. Eliseev
doaj   +1 more source

Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis. [PDF]

Front Pharmacol, 2021
Background: Hyperuricemia is involved in the risk of chronic kidney disease (CKD). However, whether urate-lowering therapy (ULT) can influence the progression of kidney function in patients with asymptomatic hyperuricemia is still controversial.
Zhang L, An K, Mou X, Zhang M, Su Q, Li S.   +5 more
europepmc   +2 more sources